Plain-English translation of NCT07082803 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lymphoma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new medication called to treat certain types of non-Hodgkin lymphoma — blood cancers that have come back or stopped responding to prior treatments. Researchers want to understand how safe this medication is, how your body processes it, and whether it can help shrink tumors. You may receive the medication alone or in combination with other lymphoma treatments.
Many patients with relapsed or refractory lymphoma have limited options after their cancer stops responding to standard treatments. This trial exists to find out whether this medication could offer a new hope for these patients.
You likely qualify if…
You likely don't qualify if…
As a participant, you will receive either as a single agent or combined with other lymphoma medications, depending on which group you are assigned to. You will have regular clinic visits to receive the medication, have blood work and scans to monitor how your body is responding, and report any side effects. The study will track how safe the medication is, how your body processes it, and whether your tumors are shrinking.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
United States